This is the VOA Special English Health Report.

    Last week, the United States government announced a major education and research campaign against Alzheimer's disease. The brain-wasting disease has no cure. The plan includes more efforts to develop drugs to prevent it.

    In the United States, more than five million people have Alzheimer's or some other form of dementia. As the population gets older, the number is expected to reach almost eight million by twenty-thirty. By then, experts say Alzheimer's and other dementia disorders could affect as many as sixty-six million people worldwide.

    The national Alzheimer's plan calls on scientists to develop treatments to prevent the disease by twenty twenty-five. Officials at the National Institutes of Health have promised fifty million dollars to help support that effort. NIH held a conference of the nation's top Alzheimer's researchers where NIH Director Francis Collins discussed the plan.
    美国阿尔茨海默氏症计划要求科学家在2025年前开发出预防这类疾病的治疗办法。美国国家卫生研究院(以下简称NIH)官员已经承诺提供5千万美元用于帮助支持这一努力。NIH负责人弗朗西斯·柯林斯(Francis Collins)在该院举办的顶尖阿尔茨海默氏症研究人员会议上讨论了这一计划。

    FRANCIS COLLINS: "We have learned more about this disease in the last couple of years than probably ever before. And now the goal is to take that and translate it into interventions."

    Early next year, scientists at the Banner Alzheimer's Institute in Arizona plan to begin human testing of an experimental drug. The drug is called crenezumab, and the hope is it will prevent Alzheimer's.

    The study will involve members of a large extended family living in villages in the Medellin area in Colombia. Some of the family members have a rare genetic disorder that causes them to get early-onset Alzheimer's. They begin to show signs of mental loss in their mid-forties and fully develop the disease by their early fifties.

    Three hundred people have agreed to be in the study. One-third of them will receive crenezumab. The others will be given a placebo, a pill that does not contain any drug. They will not know if they have been given the drug or the placebo. The study will also include a smaller number of people in the United States.

    Pierre Tariot will help lead the study, known as a human trial. He says all of the people have been informed that the drug might not work or that they might receive a placebo. Mr. Tariot says the people still wanted to be in the study.
    皮埃尔·塔里奥(Pierre Tariot)将帮助领导这项被称为人体试验的研究。他说,所有人都已经被告知,这种药物可能无效,或者他们可能只会得到安慰剂。塔里奥表示,即便如此,人们还是希望参与到研究中。

    PIERRE TARIOT: "They have been faced with this devastating illness hitting every generation for hundreds of years. As one of them put it, 'There are many rivers to cross but at least we're at the first bank.' And that's kind of the attitude that people have had."

    Scientists hope that if the drug works in those facing early-onset Alzheimer's, then it might also help older people.

    The study in Colombia could take as long as five years, but researchers believe they could get results in two years.